您查看的活动已结束

10月15日（周四），上海健谈会、禹杭资本、毕马威, 圆阳和斐药圈将共同举行主题为 "2020年医疗创业公司：在前所未有的变革中茁壮成长"的座谈会活动。

本次活动是2020全球生物经济创新创业大赛全国巡回推介会的最后一场。来不及参加推介会的选手，想了解更多大赛资讯，可以登录大赛官网查看或联系大赛组委会（手机: 18158409676）

座谈会将由毕马威生命科学行业主管合伙人胡丽芬主持，座谈嘉宾如下：

*王玉光-再极医药董事长和CEO 
*徐斌 - 辉瑞制药全球数字创新实验室（大中华区）总监
*穆克安 - 上海沃比医疗科技创始人和CEO
*王翔弘 - 阿谢资本合伙人
*谢奕彤 - 来凯医药科技（上海）运营总监

2020年对于整个医疗行业，尤其是医疗行业来说，是前所未有的变化之年：从数字医疗的超速发展，到对疫苗的更加重视，再到充满挑战的国际政治和物流环境，以及市场对医疗IPO的强烈需求。

我们的投资人和企业家嘉宾将深入分析这些变化对中国医疗创业公司意味着什么，聊聊现在的投资人和创业公司与一年前有什么不同，并就如何在新常态下繁荣发展提出见解.

On Thursday, October 15th, Shanghai Healthcare Drinks, Yuhang Capital , KPMG, ChinaMed Capital and Run Young TTO will hold a discussion panel entitled “Medical Startups in 2020: Thriving on Unprecedented Change”. 

This is the last event before the 2020 Global Bio-Economy Innovation and Entrepreneurship Competition application deadline for startups. You can see more about the competition here.

The panel will be moderated by Li Fern Woo, China Life Science Sector Head, KPMG and consist of the following executives: 

*Yuguang Wang - Chairman and CEO, Maxinovel Pharmaceuticals
*William Xu - Head of Innovation Lab (Greater China), Pfizer 
*Michael Alper - Founder and CEO, Wallaby Medical
*Garry Wang - Partner, Ashe Capital Management
*Amy Xie - VP Operations, Laekna Therapeutics

2020 has been a year of unprecedented change in general and for the medical industry in particular; from the hyper acceleration of digital health, to the increased emphasis on vaccines, to the challenging international political and logistical environment, to the strong market demand for healthcare IPOs.

Our panelists of investors and entrepreneurs will give insight into what all these changes mean for Chinese medical startups, what’s different for investors and startups now vs. one year ago and they will give insights on how to prosper in the new normal.